Abstract
Small interfering RNAs (siRNA) are emerging as a new opportunity for treatment of various diseases, including viral and cancer diseases via knocking down a specific gene that involves in disease development. But their clinical application is hampered because of susceptibility to degradation and difficult delivery of siRNA into cells. So it is needed to develop an efficient carrier that stabilizes and delivers siRNA efficiently and specifically into cells. Hollow inorganic nanoparticles have gained considerable attention as an efficient drug and gene delivery system. This is due to their biocompatibility, simple preparative processes, easy functionalization and high capacity for drug loading. Several nanoparticle platforms for siRNA delivery have been developed to overcome the major limitations facing the therapeutic uses of siRNA. Recently, researchers have developed a wide range of inorganic nanocarriers to increase efficacy of si-RNA-based drugs and gained efficient siRNA delivery both in vitro and in vivo. This review covers a broad spectrum of hollow inorganic nanoparticles as non-viral siRNA delivery systems. These nanoparticles are developed for enhanced cellular uptake and targeted gene silencing in vitro and in vivo and their characteristics and opportunities for clinical applications of therapeutic siRNA are discussed in this article. Various types of inorganic hollow nanovectors including: mesoporous silica nanoparticles, carbon nanotubes, graphene oxide, fullerenes, calcium phosphate nanoparticles, hollow manganese oxide, gold nanoshells, and layered double hydroxide nanoparticles used to deliver siRNA are introduced and the development of theranostics and combinational treatment is also discussed.
Keywords: Hollow nanoparticles, inorganic, siRNA, mesoporous silica, carbon nanotubes, graphene oxide, fullerenes, calcium phosphate nanoparticles.
Current Pharmaceutical Design
Title:Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review
Volume: 21 Issue: 29
Author(s): Jaleh Varshosaz and Somayeh Taymouri
Affiliation:
Keywords: Hollow nanoparticles, inorganic, siRNA, mesoporous silica, carbon nanotubes, graphene oxide, fullerenes, calcium phosphate nanoparticles.
Abstract: Small interfering RNAs (siRNA) are emerging as a new opportunity for treatment of various diseases, including viral and cancer diseases via knocking down a specific gene that involves in disease development. But their clinical application is hampered because of susceptibility to degradation and difficult delivery of siRNA into cells. So it is needed to develop an efficient carrier that stabilizes and delivers siRNA efficiently and specifically into cells. Hollow inorganic nanoparticles have gained considerable attention as an efficient drug and gene delivery system. This is due to their biocompatibility, simple preparative processes, easy functionalization and high capacity for drug loading. Several nanoparticle platforms for siRNA delivery have been developed to overcome the major limitations facing the therapeutic uses of siRNA. Recently, researchers have developed a wide range of inorganic nanocarriers to increase efficacy of si-RNA-based drugs and gained efficient siRNA delivery both in vitro and in vivo. This review covers a broad spectrum of hollow inorganic nanoparticles as non-viral siRNA delivery systems. These nanoparticles are developed for enhanced cellular uptake and targeted gene silencing in vitro and in vivo and their characteristics and opportunities for clinical applications of therapeutic siRNA are discussed in this article. Various types of inorganic hollow nanovectors including: mesoporous silica nanoparticles, carbon nanotubes, graphene oxide, fullerenes, calcium phosphate nanoparticles, hollow manganese oxide, gold nanoshells, and layered double hydroxide nanoparticles used to deliver siRNA are introduced and the development of theranostics and combinational treatment is also discussed.
Export Options
About this article
Cite this article as:
Varshosaz Jaleh and Taymouri Somayeh, Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review, Current Pharmaceutical Design 2015; 21 (29) . https://dx.doi.org/10.2174/1381612821666150901103937
DOI https://dx.doi.org/10.2174/1381612821666150901103937 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteinase-Activated Receptor-2: Physiological and Pathophysiological Roles
Current Medicinal Chemistry - Cardiovascular & Hematological Agents α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy
Current Topics in Medicinal Chemistry Human Cancer Cell Line Based Approach of 1,3,4-thiadiazole and its Fused Ring: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry 4'-Thionucleosides as Potent and Selective A<sub>3</sub> Adenosine Receptor Ligands
Current Organic Chemistry Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry Chemical and Biochemical Basis of Cell-Bone Matrix Interaction in Health and Disease
Current Chemical Biology MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer
Current Pharmaceutical Design Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets The Clustered DNA Lesions – Types, Pathways of Repair and Relevance to Human Health
Current Medicinal Chemistry Multiple Myeloma and the Immune Microenvironment
Current Cancer Drug Targets Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention
Current Drug Targets OIP5-AS1: A Fascinating Long Noncoding RNA in Carcinoma
Current Pharmaceutical Design Molecular Imaging of Apoptosis with Radio-Labeled Annexin A5 Focused on the Evaluation of Tumor Response to Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets
Current Drug Targets Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets Extracellular Matrix Scaffolds for Tissue Engineering and Regenerative Medicine
Current Stem Cell Research & Therapy DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design